Pulmonary inflammatory infiltration

Pulmonary inflammatory infiltration is not a single molecular target or receptor but rather a complex pathological process characterized by the movement and accumulation of inflammatory cells—such as neutrophils, lymphocytes, and macrophages—into the lung parenchyma, alveoli, or interstitial spaces (Source: StatPearls, 'Pneumonia'). This process is a hallmark of various respiratory conditions, including acute respiratory distress syndrome (ARDS), pneumonia, and interstitial lung diseases, where it often manifests as 'infiltrates' on chest radiographs or CT scans (Source: NIH, 'Pulmonary Inflammation'). The infiltration is orchestrated by an array of molecular mediators, including chemokines (e.g., IL-8), cytokines (e.g., TNF-alpha, IL-1 beta), and cell adhesion molecules like ICAM-1 that facilitate leukocyte extravasation from the blood into the lung tissue (Source: PubMed, PMID: 11592376). While not a target itself, the underlying pathways are frequently the focus of therapeutic intervention; for instance, glucocorticoids are used to broadly suppress the inflammatory signaling that drives this infiltration (Source: Mayo Clinic). Targeting the specific molecular drivers of infiltration, such as interleukin receptors or integrins, represents a major area of drug development for inflammatory lung diseases.

Other names

Pulmonary infiltrateLung infiltrationInflammatory cell infiltrationAlveolar infiltrationInterstitial infiltration

Inhibition of pro-inflammatory cytokine production, reduction of leukocyte adhesion and migration, and suppression of the overall immune response to prevent tissue damage.